slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 37,021-37,050
Pages 2,019
Rows per page 30
Component
37,021-37,050 of 60,557
23
The slide uses a process flow diagram to illustrate the randomized, double-blind, placebo-controlled study structure.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
13
Apexigen | Investor Presentation Deck | 27 slidesApexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
15
Spider plot (swimmer plot variant) showing individual patient responses over time.Apexigen | Investor Presentation Deck | 27 slides · Apexigen
Pitch deck Investor relations Beat · Traction1 hit
10
Clinical trial data comparing sublingual/oral film (AQST-109) vs intramuscular injection.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
12
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
04
The slide uses academic citations to establish the clinical relevance of the target protein.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
10
The slide uses a horizontal bar chart format to represent clinical trial stages for different drug combinations.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
Includes specific clinical metrics (ORR, mPFS, mOS) comparing patients above and below the Minimal Efficacious Concentration (MEC).Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
15
The slide includes two scatter plots with error bars and two summary tables of experimental data.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
The slide uses qualitative feedback from healthcare providers and KOLs to validate market demand.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
23
The slide includes detailed footnotes explaining specific adverse events and patient outcomes.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
24
Includes footnotes comparing results to historical METEOR and CANTATA studies.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
25
Data compares low vs high biomarker groups across different dosage cohorts.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
27
The slide uses a table to summarize key value propositions and speech bubbles to provide direct KOL validation.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
30
Data cutoff date is August 18, 2022. N=21 patients.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
31
Includes a footnote comparing results to a historical P3 study.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
33
Data shows a clear correlation between achieving MEC and better clinical outcomes in PDAC patients.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
19
The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
30
The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
38
The slide uses a process flow for the trial design and a table for disease staging and median overall survival (OS).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
42
The slide uses a map to anchor the geographic focus and a table to list specific drug approvals by disease category.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
47
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
06
The slide uses a Gantt-style visualization to show progress through Preclinical, Phase 1, and Phase 2 stages for multiple assets.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
13
The slide combines a product summary table on the left with a clinical trial line chart on the right.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
18
The slide uses a feature-comparison matrix to highlight differentiation in mechanism, duration, and distribution.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
22
Includes a quote from Keith Nuechterlein and a detailed clinical trial timeline.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
25
The slide uses a checkmark system to highlight specific advantages of RL-007 and a few competitors.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
28
Includes a sidebar summary and a clinical trial design overview.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
29
The table uses checkmarks to indicate the presence of favorable attributes across different drug classes.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
32
Includes a summary table on the left and a clinical trial roadmap/process diagram on the bottom right.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit